Lorlatinib ‘highly effective option’ for certain NSCLC patients
A head-to head trial shows it might be particularly effective in preventing intracranial progression, researchers say.
A head-to head trial shows it might be particularly effective in preventing intracranial progression, researchers say.
Neither mono nor dual immune checkpoint inhibitor therapy improved survival in multi-nation study.
But two trials of first-line therapy have differing overall survival outcomes.
The hunt is on for ways to predict response to immune checkpoint inhibitors in NSCLC.
Osimertinib is a practice-changing treatment for certain patients with completely resected EGFR-mutated disease, researcher says.
Interim results from the open-label trial suggest abemaciclib has benefit, researchers say.
Trial findings clarify lack of benefit and increased cardiopulmonary toxicity.
Trial results show improved clinical outcome in a subset of men with castration-resistant disease, researchers say.
Results from a phase 2 trial with letrozole in oestrogen receptor-positive patients.
The first results of the CheckMate 9ER trial show a good response rate and improved survival, researchers say.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.